Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

NCT02618434 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

297

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: SPN-810 (18 mg)
DRUG: SPN-810 (36 mg)
DRUG: Placebo

Sponsor

Supernus Pharmaceuticals, Inc.